Search

Multipotent adult arogenitor cells

The cells for creation of the product are isolated from a qualified donor and expanded on a large scale and then frozen until use. After administration, the cells are cleared from the body over time.

Influenza A virus A/Hawaii/66/2019 (H1N1) live (attenuated) antigen

A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. … Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3.

Influenza B virus B/Washington/02/2019 live (attenuated) antigen

A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. … Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3.

Maritime pine extract

GC-376 free acid

A prodrug of [GC-373], GC-376 has recently been used to test inhibition of SARS-Cov-2 M^pro _in vitro_, and results show potent inhibition of this target[A219036]. … The compound is known as a direct acting antiviral (DAA) for coronaviruses, and was initially developed using structure-guided design to combat MERS-Cov infections[A219036,A219056].

LNP-nCoVsaRNA Vaccine

As of July 2020, a clinical trial (COVAC1) is underway (ISRCTN17072692) to test the safety and immunogenicity of the vaccine. … LNP-nCoVsaRNA is a purified, synthetic mRNA vaccine candidate encoding the S glycoprotein of SARS-CoV-2, which is used primarily by the virus to attach to and invade human cells.

Dendritic cells vaccine

The recombinant chimeric DC vaccine is a subunit-based vaccine candidate investigated for safety and effectiveness against SARS-CoV-2-induced pneumonia. … With a better safety profile than inactivated and live-attenuated virus and virus-vector vaccines, the recombinant chimeric DC vaccine reduces the risk of virulence recovery, pre-existing anti-vector immunity

Nuvaxovid

a productive infection in humans. … (Fractions A and C from _Quillaja saponaria_ extract).

V-SARS

This therapeutic concept was applied to the development of V-SARS, which heat inactivates the plasma, and packages it into a once-daily pill form. … Immunitor Inc., the sponsor, is currently testing this oral vaccine for immunogenicity in 20 healthy volunteers in a Phase 1 clinical trial (NCT04380532).

BBV152

or a novel TLR7/8 agonist adsorbed gel. … The candidate, a whole virion inactivated SARS-CoV-2 vaccine, was developed from a well-known SARS-CoV-2 strain and a vero cell platform (CCL-81) with adjuncts of either aluminum hydroxide gel (Algel)